( of of of ...)Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C,Health

of of of treatment dosing dosing dosing, value DC=F carried (a) forward) ---------------------------------------- -------- -------- ---------- TVR + peg-IFN + RBV (arms B, C 153 of 138 of 123 of 149 of 175 and D) 175 175 175 (85%) (88%) (79%) (70%) ---------------------------------------- -------- -------- ---------- Placebo + peg-IFN + RBV (arm A) 12 of 75 8 of 75 29 of 75 32 of 75 (16%) (11%) (39%) (43%) ---------------------------------------- -------- -------- ---------- (a) Intent-to-treat, discontinuation=failure analysis. Patients who had HCV RNA (less than)10 IU/mL at the time of discontinuation are counted as "failures", however these patients will be followed post- discontinuation to determine if they achieve a sustained viral response (SVR). ---------------------------------------------------------------------

In PROVE 1, a low rate of viral breakthrough was observed. Viral breakthrough occurred in 12 patients receiving telaprevir (7%), all but one of which occurred in the first 4 weeks of treatment.

Analysis of PROVE 1 Patients who Finished All Treatment at 12 Weeks

Seventeen of 175 patients received at least one dose of telaprevir in "Arm D" of the PROVE 1 study (telaprevir + peg-IFN + RBV). According to the study protocol, patients in Arm D were eligible to stop all treatment at week 12 if they met on-treatment criteria, including the achievement of RVR ((less than)10 IU/mL at week 4) and maintenance of this viral response ((less than)10 IU/mL) at week 10 of treatment. Nine of 17 patients met these criteria and stopped therapy at 12 weeks, and 6 of these patients continued to have undetectable HCV RN
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death